Buy Ranbaxy if it falls below Rs 250: Surjit Pal
Ranbaxy might not be able to make any profits in its US operations, Surjit Pal of Prabhudas Lilladhar told NDTV after the US FDA banned the company's Toansa plant in Punjab. There is also a very high risk that the FDA will also withdraw Ranbaxy's first to file status for three molecules, he added.
